Last Price$59.76.8%
Market Cap$3,532.4M
624.1%
Industry median - 3.6%
5Y Historical average - 3,028.6%
N/A
Industry median - 8.2%
5Y Historical average - 23.9%
N/A
Industry median - (12.5%)
5Y Historical average - 0.9%
N/A
Industry median - 10.8%
5Y Historical average - 27.4%
PTGX Growth Rating
PTGX Growth rating
6.7
PTGX Growth rating performance
PTGX Growth Metrics
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
Competing with PTGX Growth
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Growth score | Revenue Growth
(5Y CAGR) | Revenue Growth
(YoY) | Revenue Growth
(FWD) | EPS Growth
(5Y CAGR) | EPS Growth
(YoY) | EPS Growth
(FWD) | FCF Growth
(5Y CAGR) | FCF Growth
(YoY) |
$3,532.4M | 6.7 | 351.7% | 624.1% | (79.0%) | N/A | N/A | (129.4%) | N/A | N/A | |
$124.8B | 6.9 | 21.5% | 11.5% | 8.6% | N/A | N/A | (962.4%) | N/A | N/A | |
$77.0B | 5.6 | 12.6% | 8.3% | 2.4% | 16.1% | 10.3% | 3.1% | 12.5% | (5.7%) | |
$34.4B | 6.3 | 106.9% | 127.3% | 76.3% | (9.7%) | (57.5%) | (132.2%) | N/A | (70.8%) | |
$30.7B | 5.4 | 59.2% | 23.0% | 28.6% | (23.2%) | (38.5%) | (26.5%) | (36.7%) | N/A | |
$24.0B | 6.2 | 90.9% | (28.0%) | (28.0%) | 36.5% | N/A | (182.9%) | (3.1%) | N/A | |
$14.5B | 4.0 | 4.5% | (3.8%) | 35.4% | (19.0%) | (9.0%) | 144.6% | 10.7% | (7.3%) | |
$13.8B | 7.5 | 14.7% | 23.6% | 9.1% | N/A | 25.6% | 6.8% | N/A | 44.5% | |
$13.4B | 7.1 | 10.8% | 17.8% | 10.0% | N/A | 152.8% | 48.9% | N/A | 820.5% | |
$13.3B | 6.1 | (100.0%) | N/A | N/A | (0.9%) | (92.8%) | 11.4% | 44.6% | 84.8% | |
$1,846.9M | 5.9 | 50.5% | 50.5% | 50.7% | 25.3% | 20.9% | (35.6%) | 3.3% | (43.8%) |
FAQ
What is the Protagonist Therapeutics, Inc. (PTGX) revenue growth?
The Protagonist Therapeutics, Inc. (PTGX) revenue growth is 624.1%, which is lower than the industry median of 3.6% and the 5-year historical average of 3,028.6%.
What is the Protagonist Therapeutics, Inc. (PTGX) operating income growth?
The Protagonist Therapeutics, Inc. (PTGX) operating income growth is N/A, compared to the industry median of 8.2% and the 5-year historical average of 23.9%.
What is the Protagonist Therapeutics, Inc. (PTGX) EPS (Earnings Per Share) growth?
The Protagonist Therapeutics, Inc. (PTGX) EPS growth is N/A, compared to the industry median of (12.5%) and the 5-year historical average of 0.9%.
What is the Protagonist Therapeutics, Inc. (PTGX) Free Cash Flow (FCF) growth?
The Protagonist Therapeutics, Inc. (PTGX) Free Cash Flow growth is N/A, compared to the industry median of 10.8% and the 5-year historical average of 27.4%.